TY - JOUR
T1 - The Yorkshire Kidney Screening Trial (YKST)
T2 - protocol for a feasibility study of adding non-contrast abdominal CT scanning to screen for kidney cancer and other abdominal pathology within a trial of community-based CT screening for lung cancer
AU - Usher-Smith, Juliet A.
AU - Godoy, Angela
AU - Burge, Sarah W.
AU - Burbidge, Simon
AU - Cartledge, Jon
AU - Crosbie, Philip A.J.
AU - Eckert, Claire
AU - Farquhar, Fiona
AU - Hammond, David
AU - Hancock, Neil
AU - Iball, Gareth R.
AU - Kimuli, Michael
AU - Masson, Golnessa
AU - Neal, Richard D.
AU - Rogerson, Suzanne
AU - Rossi, Sabrina H.
AU - Sala, Evis
AU - Smith, Andrew
AU - Sharp, Stephen J.
AU - Simmonds, Irene
AU - Wallace, Tom
AU - Ward, Matthew
AU - Callister, Matthew E.J.
AU - Stewart, Grant D.
N1 - Funding Information:
All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author). GDS has received educational grants from Pfizer, AstraZeneca, and Intuitive. Surgical; consultancy fees from Pfizer, Merck, EUSA Pharma, and CMR Surgical; travel expenses from Pfizer; and speaker fees from Pfizer. All other authors declare that (1) they have no support from or relationships with companies that might have an interest in the submitted work in the previous 3 years; (2) their spouses, partners, or children have no financial relationships that may be relevant to the submitted work; and (3) they have no non-financial interests that may be relevant to the submitted work. The corresponding author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in BMJ editions and any other BMJPGL products and sub-licences to exploit all subsidiary rights, as set out in our licence ( http://resources.bmj.com/bmj/authors/checklists-forms/licence-for-publication ). The corresponding author affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.
Funding Information:
This study is funded by Yorkshire Cancer Research grant number L403C. The qualitative substudy is funded by a grant from Kidney Cancer UK. GDS is supported by The Mark Foundation for Cancer Research, the Cancer Research UK Cambridge Centre (C9685/A25177) and NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). PAJC is supported by the Manchester National Institute for Health Research Manchester Biomedical Research Centre (IS-BRC-1215-20007). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.
Funding Information:
This study is funded by Yorkshire Cancer Research grant number L403C. The qualitative substudy is funded by a grant from Kidney Cancer UK. GDS is supported by The Mark Foundation for Cancer Research, the Cancer Research UK Cambridge Centre (C9685/A25177) and NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). PAJC is supported by the Manchester National Institute for Health Research Manchester Biomedical Research Centre (IS-BRC-1215-20007). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.
Publisher Copyright:
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.
PY - 2022/9/20
Y1 - 2022/9/20
N2 - Introduction Kidney cancer (renal cell cancer (RCC)) is the seventh most common cancer in the UK. As RCC is largely curable if detected at an early stage and most patients have no symptoms, there is international interest in evaluating a screening programme for RCC. The Yorkshire Kidney Screening Trial (YKST) will assess the feasibility of adding non-contrast abdominal CT scanning to screen for RCC and other abdominal pathology within the Yorkshire Lung Screening Trial (YLST), a randomised trial of community-based CT screening for lung cancer. Methods and analysis In YLST, ever-smokers aged 55-80 years registered with a general practice in Leeds have been randomised to a Lung Health Check assessment, including a thoracic low-dose CT (LDCT) for those at high risk of lung cancer, or routine care. YLST participants randomised to the Lung Health Check arm who attend for the second round of screening at 2 years without a history of RCC or abdominal CT scan within the previous 6 months will be invited to take part in YKST. We anticipate inviting 4700 participants. Those who consent will have an abdominal CT immediately following their YLST thoracic LDCT. A subset of participants and the healthcare workers involved will be invited to take part in a qualitative interview. Primary objectives are to quantify the uptake of the abdominal CT, assess the acceptability of the combined screening approach and pilot the majority of procedures for a subsequent randomised controlled trial of RCC screening within lung cancer screening. Ethics and dissemination YKST was approved by the North West-Preston Research Ethics Committee (21/NW/0021), and the Health Research Authority on 3 February 2021. Trial results will be disseminated at clinical meetings, in peer-reviewed journals and to policy-makers. Findings will be made available to participants via the study website (www.YKST.org). Trial registration numbers NCT05005195 and ISRCTN18055040.
AB - Introduction Kidney cancer (renal cell cancer (RCC)) is the seventh most common cancer in the UK. As RCC is largely curable if detected at an early stage and most patients have no symptoms, there is international interest in evaluating a screening programme for RCC. The Yorkshire Kidney Screening Trial (YKST) will assess the feasibility of adding non-contrast abdominal CT scanning to screen for RCC and other abdominal pathology within the Yorkshire Lung Screening Trial (YLST), a randomised trial of community-based CT screening for lung cancer. Methods and analysis In YLST, ever-smokers aged 55-80 years registered with a general practice in Leeds have been randomised to a Lung Health Check assessment, including a thoracic low-dose CT (LDCT) for those at high risk of lung cancer, or routine care. YLST participants randomised to the Lung Health Check arm who attend for the second round of screening at 2 years without a history of RCC or abdominal CT scan within the previous 6 months will be invited to take part in YKST. We anticipate inviting 4700 participants. Those who consent will have an abdominal CT immediately following their YLST thoracic LDCT. A subset of participants and the healthcare workers involved will be invited to take part in a qualitative interview. Primary objectives are to quantify the uptake of the abdominal CT, assess the acceptability of the combined screening approach and pilot the majority of procedures for a subsequent randomised controlled trial of RCC screening within lung cancer screening. Ethics and dissemination YKST was approved by the North West-Preston Research Ethics Committee (21/NW/0021), and the Health Research Authority on 3 February 2021. Trial results will be disseminated at clinical meetings, in peer-reviewed journals and to policy-makers. Findings will be made available to participants via the study website (www.YKST.org). Trial registration numbers NCT05005195 and ISRCTN18055040.
KW - computed tomography
KW - kidney tumours
KW - urological tumours
KW - Early Detection of Cancer/methods
KW - Kidney Neoplasms/diagnostic imaging
KW - Tomography, X-Ray Computed/methods
KW - Humans
KW - Lung Neoplasms/diagnosis
KW - Carcinoma, Renal Cell
KW - Kidney/pathology
KW - Feasibility Studies
KW - Randomized Controlled Trials as Topic
UR - http://www.scopus.com/inward/record.url?scp=85138152915&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2022-063018
DO - 10.1136/bmjopen-2022-063018
M3 - Article
C2 - 36127097
AN - SCOPUS:85138152915
SN - 2044-6055
VL - 12
JO - BMJ Open
JF - BMJ Open
IS - 9
M1 - e063018
ER -